August 5, 2016

Bristol-Myers drug fails lung cancer study, shares plunge

Bristol-Myers drug fails lung cancer study, shares plunge
In this June 15 2005 file photo, a sign stands in front of the Bristol-Myers Squibb Company's headquarters in Lawrence Township, N.J. Bristol-Myers Squibb Co.'s blockbuster cancer treatment Opdivo failed a key study focusing on its use as a lone treatment for lung cancer, prompting a stock plunge, Friday, Aug. 5, 2016. The drug is already approved as a treatment for melanoma, kidney cancer and lung cancer following chemotherapy. (AP Photo/Mel Evans, File)

A blockbuster cancer treatment failed in a key study as the drug's maker, Bristol-Myers Squibb, attempts to extend its usage for lung cancer patients.

Shares of the New York company plunged 16 percent Friday, its biggest one-day drop in 14 years. Shares of rival Merck & Co., which makes a rival cancer drug, spiked 10 percent to reach an 18-year high.

Bristol's drug, Opdivo, and Merck's drug Keytruda are immunotherapies, which bolster the immune system so that patients can better fight cancer. Both drugs are already approved to treat melanoma and lung cancer, but only after chemotherapy.

In June, Merck reported positive results from a key study focusing on Keytruda as a lone treatment for lung cancer. The negative results from Bristol appear to put Merck in the lead for treating cancer patients without resorting to chemotherapy and its drastic side effects.

The latest late-stage study for Opdivo involved 541 patients who had received no prior treatment for lung cancer.

"We remain committed to improving patient outcomes through our comprehensive development program," said Bristol-Myers CEO Dr. Giovanni Caforio.

Shares of Bristol-Myers Squibb Co. slumped $12.04 to $63.28.

© 2016 The Associated Press. All rights reserved.

Citation: Bristol-Myers drug fails lung cancer study, shares plunge (2016, August 5) retrieved 23 April 2024 from https://medicalxpress.com/news/2016-08-bristol-myers-drug-lung-cancer-plunge.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

FDA approves Bristol-Myers drug for new use in kidney cancer
2 shares

Feedback to editors
Active military service may heighten women's risk of having low birthweight babies

9 hours ago
Significant global variation in COVID-19 guidelines: Most countries recommend at least one treatment that doesn't work

9 hours ago
Study connects enjoyment of nature to lower inflammation levels

9 hours ago
Bacteria in the intestine that change in response to inflammation could have an impact on our immune system

10 hours ago
Researchers develop deep-learning model capable of predicting cardiac arrhythmia 30 minutes before it happens

11 hours ago
Improving cancer immunotherapy by prolonging T-cell survival

11 hours ago
Eye-opener: Pupils enlarge when people focus on tasks

11 hours ago
Study finds COVID-19 pandemic led to some, but not many, developmental milestone delays in infants and young children

11 hours ago
Common antibiotic may be helpful in fighting respiratory viral infections

11 hours ago
In psychedelic therapy, clinician-patient bond may matter most

12 hours ago
Load comments (0)